Merck Acquires Bio-Techne in $11.3 Billion Deal

Germany's Merck KGaA agreed to acquire Minneapolis-based TECH (Bio-Techne) for $73 per share in cash — an $11.3 billion deal representing a 24% premium to Bio-Techne's June 24 closing price and 36% above its one-month volume-weighted average. Bio-Techne surged more than 20% to close at $70.67, becoming the top S&P 500 gainer on the day, with the stock trading near the offer price suggesting minimal deal-closing risk in arbitrage markets. Merck shares rose roughly 3%.

The acquisition is Merck KGaA's largest since the $17 billion Sigma-Aldrich deal in 2015 and arrives two months after incoming CEO Kai Beckmann took the helm with a mandate to expand the Life Science segment. Bio-Techne's 3,000+ employees operate across 34 global locations, generating over $1.2 billion in fiscal 2025 sales through two segments: Protein Sciences (72%) — covering high-quality biological reagents for cell and gene therapy — and Diagnostics & Spatial Biology (28%). Merck projects approximately €140 million in annual cost synergies, fully realized within three years, with EPS accretion on the same timeline.

The deal is happening into a robust M&A environment: healthcare acquisitions have already totaled $419 billion in 2026, the most since 2021. Analyst Puneet Souda at Leerink called Bio-Techne an 'attractive asset' at the acquisition price, noting current pressures in the research tools market make the valuation reasonable for a long-term strategic buyer. Regulatory approval and a Bio-Techne shareholder vote are expected before close in late 2026 or early 2027, with no major antitrust concerns flagged by analysts covering the life sciences tools sector.